ライフサイエンスコーパス: SGLT

1 SGLT inhibition might also be considered in conjunction

2 SGLT-1 protein expression was unaltered; however, HS inc

3 ut mice lacking sodium glucose tranporter-1 (SGLT-1) or the short chain fatty acid sensing receptor F

4 cells via the sodium glucose transporter 1 (SGLT-1) and glucose transporter 2 (GLUT2); various pepti

5 ibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

6 Sodium-glucose co-transporters 2 (SGLT-2) inhibitors have emerged as a novel antidiabetic

7 s are seen in real-world practice and across SGLT-2i class.

8 ether with Western blot analysis revealed an SGLT-like protein.

9 ther a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to i

10 ose uptake in fresh isolated tumors using an SGLT-specific radioactive glucose analog, alpha-methyl-4

11 P-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors and increased with sulfonylureas, thia

12 We determined levels of GLUT2 and SGLT-1 proteins and phosphorylation of AMPKalpha2 by imm

13 ice aiming to evaluate the role of GLUTs and SGLTs in controlling glucose distribution and utilizatio

14 and death in patients newly initiated on any SGLT-2i versus other glucose-lowering drugs in 6 countri

15 ose and alpha-MDG are abolished by arresting SGLT activity by sodium removal or the SGLT inhibitor ph

16 ctivities of the Na(+)/glucose cotransporter SGLT-1 and GLUT2 were unaffected in LEPR-B-KO jejunum, w

17 se reuptake by sodium/glucose cotransporter (SGLT) 2 in the kidney, without affecting intestinal gluc

18 selective for sodium-glucose cotransporter (SGLT) family members and the sweet taste receptor were t

19 The Na-glucose cotransporter (SGLT) was the first transporter ever to be cloned.

20 (depolarizing) sodium-glucose cotransporter (SGLT).

21 the sodium-dependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control bl

22 but requires sodium/glucose cotransporters (SGLT).

23 gut and renal sodium-glucose cotransporters (SGLTs) has been proposed as a novel therapeutic approach

24 The two main sodium-glucose cotransporters (SGLTs), SGLT1 and SGLT2, provide new therapeutic targets

25 l tubules via sodium-glucose cotransporters (SGLTs).

26 es in sodium-dependent sugar cotransporters (SGLTs).

27 e 309 056 patients newly initiated on either SGLT-2i or other glucose-lowering drugs (154 528 patient

28 Propensity score for SGLT-2i initiation was used to match treatment groups.

29 8]-fluoro-d-glucose (4-FDG), a substrate for SGLTs and GLUTs; and 2-deoxy-2-[F-18]-fluoro-d-glucose (

30 d-glucopyranoside (Me-4FDG), a substrate for SGLTs; 4-deoxy-4-[F-18]-fluoro-d-glucose (4-FDG), a subs

31 AMPKalpha2 and a rapid increase of the GLUT2/SGLT-1 protein ratio in the brush border membrane.

32 tested whether glucose transporters (GLUTs, SGLTs) destined for the plasma membrane are active durin

33 Compared with the control group, SGLT-2 inhibitors group had significantly reduced fastin

34 with those for alpha-glucosidases and human SGLT type 1 (hSGLT1), a well characterized sodium/glucos

35 etic ketoacidosis (DKA) (n = 16) was seen in SGLT-2 inhibitors group.

36 he sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes

37 , with potential applicability to the larger SGLT family of important sodium:solute cotransporters.

38 e transport by vSGLT is similar to mammalian SGLTs and that further studies on vSGLT will provide nov

39 e insulin-independent mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering

40 of this study was to determine the effect of SGLT-mediated glucose uptake on NHE3 activity in the ren

41 shown the blood glucose-lowering efficacy of SGLT inhibitors in type 2 diabetes when administered as

42 Notably, pharmacologic inhibition of SGLT activity by Phlorizin produced a marked inhibition

43 2 phosphorylation and modifying the ratio of SGLT-1:GLUT2.

44 imaging in the investigation of the role of SGLT transporters in human physiology and diseases such

45 A meta-analysis was conducted on trials of SGLT-2 inhibitors in patients with T1DM on insulin thera

46 work provides further support for the use of SGLT imaging in the investigation of the role of SGLT tr

47 Use of SGLT-2i, versus other glucose-lowering drugs, was associ

48 ematocrit was observed in EMPA-REG and other SGLT-2 inhibitors studies.

49 tal structure of the Vibrio parahaemolyticus SGLT showed that residue Gln(428) interacts directly wit

50 n by sodium glucose co-transporter proteins (SGLTs) in the kidneys is a relatively new strategy for t

51 Additionally, Phlorizin-sensitive SGLT transporters and NHE3 interact functionally in the

52 Seven SGLT isoforms (SGLT1 to 6 and sodium-myoinositol cotrans

53 sporters (GLUTs), sodium-glucose symporters (SGLTs), and SWEETs.

54 The present study demonstrates that SGLT-2 inhibitors are effective as adjunct therapy to in

55 2%, and 5% of the total exposure time in the SGLT-2i class, respectively.

56 cterized sodium/glucose cotransporter of the SGLT family.

57 sporter (vSGLT) is a bacterial member of the SGLT gene family.

58 on of the selectivity characteristics of the SGLT isoforms (SGLT1 transports both glucose and galacto

59 To assess the efficacy and safety of the SGLT-2 inhibitors as adjunct therapy to insulin in T1DM,

60 sting SGLT activity by sodium removal or the SGLT inhibitor phloridzin.

61 ne (BBM) via a sodium-dependent transporter, SGLT, and exit across the basolateral membrane via facil

62 ance of sodium-coupled glucose transporters (SGLTs) and facilitative glucose transporters (GLUTs) in

63 , the sodium-dependent glucose transporters (SGLTs), in pancreatic and prostate adenocarcinomas, and

64 active sodium-coupled glucose transporters (SGLTs).

65 rization and excitation by glucose-triggered SGLT activity may ensure that GE neurones continue to se

66 d by GLUTs; and (iii) measurement of in vivo SGLT activity in mouse models of pancreatic and prostate

67 ose uptake into the brain and liver, whereas SGLTs are important in glucose recovery in the kidney.

68 However, it remains to be determined whether SGLT-mediated glucose uptake regulates NHE3-mediated NaH

69 associated with similar HbA1C levels, while SGLT-2 inhibitors offered the lowest odds of hypoglycemi

70 nital mycotic infections were increased with SGLT-2 inhibitors.

71 the increased haematocrit levels noted with SGLT-2 inhibitors?

72 is large multinational study, treatment with SGLT-2i versus other glucose-lowering drugs was associat